Dynogen’s GI, GU Products To Benefit From $50M Round (BioWorld Today)
News | 04. 20. 2004
In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical com- pounds.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.